Although ARNIs were not shown to decrease AF incidence compared to Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin II Receptor Blocker (ARB)s in a meta-analysis and in a PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) post-hoc analysis, it was associated with favorable atrial remodeling after CA compared to valsartan [22, 23]. Here, ACE is linked to atrial fibrillation.